Currently ranked at 10th in the Indian Pharmaceutical Market, Intas is one of the fastest growing Indian pharmaceutical majors, having 2.9% market share. Driven by a sustainable business model, Intas has been consistently outperforming the market with a 14% CAGR. Its 8 Strategic Business Units employ a multidivisional model, with 35+ marketing divisions catering to various therapy areas for enhanced focus towards brand development. On the foundation of this diversified revenue base, Intas has gained a dominant presence in India with an expanding market share and improving ranks across years.
50% of Intas’ total domestic revenue is generated from Neurology, Psychiatry and Cardiovascular therapies. The current emphasis is on Central Nervous System (CNS), Nephrology, Cardiovascular, Diabetology, Gastroenterology, Urology and Pain Management therapies. While Intas enjoys leadership status in the CNS segment, it has also been rapidly gaining equity in Oncology, Rheumatology, Ophthalmology, Dermatology and Infertility segments.
Intas enjoys exhaustive coverage of key specialties like Neurologists, Psychiatrists, Cardiologists, Diabetologists, Consulting Physicians, Urologists, Nephrologists & Oncologists with a substantial* prescriber base. The company operates through 40 exclusive and dedicated sales depots and has established relationships with over 4,000 stockists in India. A dedicated sales representative team of 6,000+ covers more than 2,50,000 medical practitioners and 1,50,000 retail outlets across geographies including metro markets, semi-urban markets and rural markets. Intas also has a well-spread institutional presence with coverage of over 600 corporate hospitals & nursing homes.
The company is set to enhance its presence in the market through its active progress in NDDS. Currently, Intas has launched 3 NDDS products in India using patented technology.
Intas’ state-of-the-art manufacturing facilities in India cater to the domestic demand by producing various dosage forms including solid orals, biosimilars, liquids, lyophilized sterile preparations, creams, drops and injectables.
#1 : IMS TSA MAT Jul 2018, CAGR of last 5 years,: *substantial – indicating a base of over 75%
Core competency across biosimilar and plasma derived products makes Intas’ Biologics Unit one of its fastest growing franchise. Keeping patient’s welfare and wellbeing at the forefront, since the year 2000 it has been developing bio-therapeutics that meet the highest quality standards and making them available at affordable prices.
Leveraging its R&D strengths and state-of-the-art manufacturing facilities, Intas’ Biologics BU has been focused on developing high-quality recombinant DNA protein (rDNA) products and plasma derived products to address unmet medical needs across various therapeutic areas such as Oncology (Cancer), Auto-Immune, Ophthalmology, Nephrology, and Plasma derived product based therapies.
Intas’ R&D capabilities and a pool of Scientists from world class institutes across the globe, coupled with a cutting-edge technology platform and know-how has made it possible to build a robust yet niche product portfolio consist of 11 commercialized products, 8 rDNA products including 1 monoclonal antibody, and 3 plasma derived products. In addition, the company has as on date 12 products in its pipeline. In addition, several products are exported to many countries under various distribution and licensing agreements.
Being first is a norm at Intas Biologics, with a rich product portfolio of biosimilars across microbial and mammalian cell culture products like Neukine® (GCSF), Erykine® (EPO), Intalfa® (IFN), Pegasta® (Peg GCSF), Terifrac® (Teriparatide), Mabtas® (Rituximab), Folisurge®(FSH) which are testament to its innovative expertise. It is India’s first biosimilars manufacturing unit to receive European Union – Good Manufacturing Practice (EU-GMP) certification for the Drug Substance (microbial) and Drug Product manufacturing facilities, attesting to the highest quality of manufacturing and quality systems. In addition to the EU-GMP, Intas’ Biological BU facilities are approved by various other regulatory agencies such as ANVISA, GCC, MCC, Indonesia, etc.
Plasma Derived Products
Intas also operates in the field of Plasma derived products and therapies with proven technical capabilities. The current product portfolio has 3 products and there are several others under development.
Intas’ manufacturing capabilities are aligned with a business strategy of developing and commercializing highest quality products across the globe. Intas has extensive capabilities to develop and manufacture recombinant proteins, monoclonal antibodies, pegylated technology platform products and plasma derived products.
Microbial Fermentation & Mammalian Cell Culture Manufacturing Facilities
The company’s capabilities encompass small-scale to large-scale microbial fermentation, mammalian cell culture, protein & antibody purification, pegylation, lyophilization, aseptic formulation and fill-finish. With complete backward integration, the facility carries-out bulk-drug manufacturing and formulation fill-finish activity for pre-filled syringes, vials and pen-fill for devices. Intas’ International GMP compliant manufacturing facilities are supported by modern process development and quality control infrastructure. These facilities are accredited by the local and international regulatory agencies. The manufacturing facility has garnered European Union – Good Manufacturing Practice (EU-GMP) certification for Drug Substance and Drug Product.
Intas’ Quality Promise
- Independence of quality from manufacturing operations
- Well defined quality checks and documented quality assurance systems for development, release and distribution of products
- Continuous training of employees at all levels
- Constant review mechanism for continuous improvement
Intas is also one of the renowned leaders in animal healthcare companies in India, specializing in large animals and pet segments. Intas Animal Health is determined to make a difference in the prospects of animal health care by launching innovative products for the livestock, companion animals, equine, swine and poultry while also taking educational initiatives, and sponsoring programs that address current and emerging animal health needs.
Intas Animal Health is amongst the youngest players in the Indian Animal Health industry which is primarily dominated by organizations operating in the market for more than 30 years. Intas launched its Animal Health Business in 1997 and today enjoys tremendous goodwill among veterinarians across the country and is ranked No.1 in terms of initiatives for Veterinary profession. Intas operates with a focus on prime quality products, new technology, customer convenience and innovative packaging.
Intas Animal Health is recognized for its cutting-edge research and new product development. Through its well acknowledged Journal Polivet, World Veterinary Day Celebrations, Round Table Conferences and Animal Health Camps, it has build up strong partnerships with the animal healthcare providers and veterinary community. The Division has developed meaningful linkages between veterinary professionals, research institutes and industry, to serve the end customer.
Being the fastest growing Animal Health Company in India, today Intas ranks among the Top 10 Animal Health companies. It also enjoys the distinction of the fourth largest player in the livestock business segment.
Intas Animal Health has been growing much faster than the market and also has the distinction of being recognized globally for its initiatives. A testimony to this fact is winning the Animal Pharm Global Excellence Award in UK in the year 2007.
Intas Animal Health Domestic Business splits into two SBUs (Neovet & Bovicuraa) based on customers and market need verticals.
Neovet offers product mix of primarily scientific and prescription driven therapies based on disease of high occurrences and economic importance in Cattle segment. The key therapies of division are Anti-infectives (Parenteral & Oral), NSAIDs, Reproduction care, Injectable tonics and specialty products including Intra-mammary, Anti-haemoprotozoal drugs and High volume Parenteral Infusions.
Companion Animal healthcare product range is promoted by dedicated task force based in Metros and Tier-1 cities. The mainstream product range includes Anti-parasites, Skin Care, Anti-infectives, Nutraceuticals and Cosmeceuticals.
Bovicuraa offers Nutritional and Managemental product basket aimed to augment farm’s productivity and profitability. The main therapies are Oral Nutritionals including Calcium, Multi-mineral, vitamin supplements, Fat and Energy boosters, Anthelmintics, Mastitis management and specialty products to enhance performance of dairy animals’ Synbiotics, metabolic boosters and rumenotorics. The niche segment of Caprine & Ovine (Sheep &Goat) is also represented by regional task force based in high density markets like Rajasthan, Andhra Pradesh and Karnataka.
On the International front, operations have just taken off and European business was also kicked off in the year 2009. Intas Animal Health is also in the process of registering differentiated products in the developed markets of US and Canada and key semi-regulated and emerging markets.
For more information, please visit www.intasanimalhealth.com